FREMONT, Calif. – June 17, 2025 – Celltrio®, a trailblazing life sciences company specializing in advanced automation solutions for cell culturing and cell and gene therapy, has successfully closed a $15 million financial investment round. Led by Premier Partners, a prominent investor in healthcare innovation, this funding marks a pivotal moment for Celltrio as it accelerates its mission to transform biomanufacturing through cutting-edge automation.
The investment will fuel the global expansion of Celltrio’s flagship product, RoboCell, a modular platform designed to automate the entire process of sterile cell culturing and cell therapy manufacturing. RoboCell® delivers high-throughput, consistent results for biopharmaceutical companies, cell therapy developers, and regenerative medicine laboratories, addressing critical bottlenecks in the production process. The funds will be allocated to scaling manufacturing capabilities, expanding commercial operations across North America, Europe, and Asia, and advancing innovation in GMP (Good Manufacturing Practice)-ready automation solutions.
“This investment marks a major milestone for Celltrio and validates our mission to streamline, scale, and standardize cell manufacturing through automation,” said Charlie Duncheon, CEO of Celltrio. “With the support of Premier Partners, we are well-positioned to meet the growing global demand for efficient, scalable solutions in cell and gene therapy.”
Premier Partners, known for its growth equity and buyout investments, expressed strong confidence in Celltrio’s vision and technology. “We are highly impressed by Celltrio’s customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation,” said Jay Song, CEO of Premier Partners. The firm’s leadership sees Celltrio’s RoboCell® platform as a game-changer in addressing the complexities of biomanufacturing, paving the way for faster and more reliable therapeutic development.
Celltrio’s technology comes at a critical time as the cell and gene therapy market continues to grow rapidly. The company’s automation solutions reduce manual labor, minimize errors, and enhance scalability, enabling researchers and manufacturers to accelerate the journey from research to life-saving therapies. The RoboCell® system, in particular, has garnered attention for its ability to operate 24/7 in GMP-compliant environments, making it a vital tool for biopharma and regenerative medicine labs.
Posts on X have echoed the excitement surrounding the investment, with users highlighting Celltrio’s potential to redefine cell and gene therapy automation. One post noted that the company’s robotics platform, engineered by Charlie Duncheon, Jin-Oh Kim, and Raphael Kim, is already integrating with major players in the industry, signaling strong market confidence in Celltrio’s vision.
This $15 million investment round positions Celltrio to meet the rising demand for automated solutions in the life sciences sector. By expanding its global footprint and enhancing its technological offerings, Celltrio is poised to play a leading role in shaping the future of cell and gene therapy manufacturing.
About Celltrion
Celltrion is a Fremont, California-based life sciences company dedicated to advancing automation in cell culturing and cell and gene therapy. Its flagship RoboCell® platform offers fully automated, sterile, and GMP-compliant solutions for biopharmaceutical, cell therapy, and regenerative medicine applications, driving efficiency and scalability in therapeutic development.
About Premier Partners
Premier Partners is a leading investment firm specializing in growth equity and buyout investments, with a focus on healthcare innovation. The firm partners with companies that demonstrate strong potential to address critical market needs through transformative technologies.
